FibroGen
Dr. Carter, Chief Scientific Officer, joined FibroGen in September of 2020. Dr. Carter oversees FibroGen’s scientific and preclinical efforts. He brings more than 20 years of global biopharmaceutical leadership and experience, with deep expertise in drug discovery.
Prior to joining FibroGen, Percy served as Global Head of Discovery Sciences at Janssen, worked in collaboration with therapeutic area discovery scientists and other stakeholders to define and operationalize innovative strategies for the successful identification and optimization of novel small molecule, peptide, and RNA-based drug candidates. Prior to his role with Janssen, Percy was Senior Vice President and Head of Discovery for Bristol-Myers Squibb (BMS).
Prior to that, he was Senior Vice President and Head of Discovery Chemistry & Molecular Technologies and was Site Lead for the Biocon-BMS R&D Center in Bangalore, India. Percy began his career as a Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals. Dr. Carter received his bachelor’s degree in Organic Chemistry from Dartmouth College, his Ph.D. in Chemistry & Chemical Biology from Harvard University, and completed a post-doctoral fellowship at Harvard Medical School and Massachusetts General Hospital. In 2014, he received his M.B.A. from the Massachusetts Institute of Technology.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.